All News
Low Risk of TB with Secukinumab
JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were f
Read Article
Mortality Risk in Rheumatoid Lung Patients
A Medicare claims analysis of rheumatoid arthritis (RA) patients showed that RA-associated interstitial lung disease (RA-ILD) was seen in nearly 5% of patients and was found to increase mortality risks, including respiratory and cancer mortality not explained by other factors.
Read Article
Epidemiologic study of #SLE from CDC & lupus registries estimates there are 204,295 SLE pts in USA (2018). Prevalence=72.8 SLE/100,000 and is 9 X higher in females than males (129 vs 14.6/100,000), especially among Ame Indians/Alaska Natives, Black females https://t.co/5yHVQ9UqZ4
Links:
Dr. John Cush RheumNow ( View Tweet)
My note to the FDA staff: https://t.co/n2Pr2Kzrre
Dr. Janet Woodcock DrWoodcockFDA ( View Tweet)
Toci led to poorer outcomes in this study. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ https://t.co/95zaq2CEUU
Dr Philip Robinson philipcrobinson ( View Tweet)
UTSW Rheum Grand Rounds - IgG4 Dz - Plasmablasts may be a useful biomarker; but is not generally available in clinical labs (must be done on fresh whole blood) @UTSWIMchief https://t.co/GlEKw0KD3O
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - IgG4 Dz common lab findings: hypergammaglobulinemia is common but elevated ESR/CRP are not. Most have elevated IgG4 serum levels @UTSWIMchief https://t.co/wR5FEqZTsX
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - IgG4 Dz commonly presents as major salivary and lacrimal gland enlargement, orbital disease, autoimmune pancreatitis, retroperitoneal (mass) fibrosis or tubulointerstitial nephritis. @UTSWIMchief
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - IgG4 Dz renal involvement; most common is tubulointerstitial nephritis
@UTSWIMchief https://t.co/q8dZbgmvfK
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - Dr. Andres Quiceno on "IgG4 related Disease" Histologic criteria req >40% on IgG4/IgG cells @UTSWIMchief https://t.co/2kOioCdFiM
Dr. John Cush RheumNow ( View Tweet)
Being "busy" is about priorties and productivity.
Dr. John Cush RheumNow ( View Tweet)
Inequities in Telemedicine During COVID-19
Health equity in the telehealth age has assumed added importance since the COVID-19 pandemic began but what if you don't have access to reliable technology? The problem spreads beyond that though.
https://t.co/L8nvUbOqHA https://t.co/SZSmerQGEY
Links:
Dr. John Cush RheumNow ( View Tweet)
Osteoporosis in Men - is often unrecognized till they fracture. Risk factors for OP in men:
- Meds: steroids; PPI immunosuppressives
- Chronic renal disease
- Smoking, ^^alcohol
- Sedentary lifestyle
- Elderly
- Family history: Osteoporosis
https://t.co/V4P5wey070
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats – Top presentations in nr-axSpA, AS, axial PsA
Sponsored by Novartis Medical Affairs
Unable to attend all the key sessions at #ACR20? Listen to the experts as they present their views on the top abstracts.
https://t.co/r5Cf4WS63s https://t.co/zN99Jo9bO0
Links:
Dr. John Cush RheumNow ( View Tweet)
Results from Cohort Hip & Cohort Knee study (early symptomatic hip OA pts) finds that 1/9 went on to receive hip replacement during the 10-year follow-up. Clinical hip and Xray (ROA) OA increased over 10 yrs - ROA 19% to 49%, and clinical hip OA 27% to 43% https://t.co/AJXlkAxZiF https://t.co/PSY4ueXOsC
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr Stanley Cohen has written a nice review of VTE with JAK inhibitors, points out that little/no risk during developmental trials, is not the same as a low risk seen with long term use in real world patients (older, higher BMI, more activity) https://t.co/0utVMqHdf9
Dr. John Cush RheumNow ( View Tweet)
Swedish Rheumatology Quality Register study of 46316 RA pts (322601 visits) shows RA has a higher risk of venous thromboembolism (RR 1.88;95% CI 1.65, 2.15) & this increased with disease activity (RR=2.03;1.73 to 2.38) (compared to remission). https://t.co/R59tLy8WGx
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Janet Woodcock has been appointed the interim head of the FDA. President Biden has yet to nominate a new FDA commissioner. Dr. Woodcock is a rheumatologist and current Director of CDER at the FDA .https://t.co/Wk0auZ2pn1
Links:
Dr. John Cush RheumNow ( View Tweet)
Sign up to attend RheumNow Live--March 20 and 21. CME credits available
https://t.co/vJlU0Z3Q3x https://t.co/Z0ectgFD2d
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats – top presentations in Still’s disease
Sponsored by Novartis Medical Affairs
Unable to attend all the key sessions at ACR Convergence 2020? Listen to the experts as they present their views on the top abstracts.
https://t.co/MD6lU5oIvy https://t.co/CHRy3yeTwN
Links:
Dr. John Cush RheumNow ( View Tweet)